syspharm retweeted
Modelling study shows high efficacy of #PrEP in women countries with high #HIV prevalence. Risk of infection could be reduced by more than 90%. Publication of an international research team led by the #RKI in @NatureMedicine.
nature.com/articles/s41591-0…
syspharm retweeted
Modeling shows that antiretroviral treatment as pre-exposure prophylaxis (PrEP) can be highly effective in cisgender women at preventing #HIV-1 acquisition, but underscores the need to understand the barriers that limit PrEP adherence in women. nature.com/articles/s41591-0…
We just submitted our comprehensive analysis of #truvada based #prep efficacy against #HIV infection in women: shorturl.at/cfuB8. We hope that the work will clarify apparent mis-conceptions regarding gender-differences in PrEP efficacy and Prep adherence demands.
Just uploaded our comprehensive analysis of systematic sequencing errors in Oxford #nanopore Technology-based direct #rna sequencing (
@seq_rna). shorturl.at/cx368. Hope this work will contribute to the further development of the technique and #transcriptome analysis.
syspharm retweeted
New work by Redmond Smyth lab @Helmholtz_HIRI: Comprehensive functional and structural probing of the HIV-1 5’ untranslated region reveals novel interactions that regulate RNA dimerization, Pr55Gag binding and genome packaging into virions. #openaccess nature.com/articles/s41594-0…
syspharm retweeted
Our Forschungsgruppe RobustCircuit is finally official! Thanks to @dfg_public and our speaker @HiesingerLab and all members from #Berlin @Wernet_Lab @SystemPharm, Sigrist lab, Petzoldt lab, Baum lab, Schreiber lab and #Mainz @marion_silies @crlttmrtll, Ryglewski lab Duch lab.
#DFG-#Forschungsförderung für acht neue #Forschungsgruppen: Die Verbünde erhalten insgesamt rd. 43,3 Mio. € für die erste #Förderperiode. Sie forschen u.a. zur Entwicklung des Gehirns, zu #Psychotherapie|erfolg sowie zu den Ursachen von #Hochwasser. Mehr: dfg.de/service/presse/presse…
Excited to share our latest article published in @ploscompbiol: journals.plos.org/ploscompbi… #ploscompbiolauthor . We developed a new method to estimate #Prep efficacy against #HIV infection for arbitrary drug-dosing schemes
We could finally show that hot flies have less synapses, or: Brain connectivity inversely scales with developmental temperature in Drosophila cell.com/cell-reports/fullte…
syspharm retweeted
Congratulations to the @rki_de team led by MATH+ PI Max von Kleist on the publication in @NatureComms! They used a method, GInPipe, to estimate #SARS_CoV_2 incidences and the number of unreported cases. It is based on publicly available viral genomes.
➡️ go.nature.com/3ELy1wj
For the World AIDS day, the BMBF published an article regarding our work on HIV-pre-exposure prophylaxis tinyurl.com/3jbhj56u
Investigation of a Limited but Explosive COVID-19 Outbreak in a German Secondary School @SSRN papers.ssrn.com/sol3/papers.…
Check out our new method for the stochastic simulation of spreading dynamics on adaptive networks! bit.ly/3xjDdV5
Read our latest #research on [#Covid_19], published with @SpringerNature in [@NatureComms]. We developed #methods for incidence estimation from #SARSCoV2 #Genomics data: rdcu.be/czuWl
Excited to share our new paper on the caveats and challenges in inferring #GeneRegulatoryNetworks from #singlecell RNAseq temporal data. Thanks to our colleagues @AiBiology and
@ZuseInstitute !!
We developed some very efficient methods for estimating the efficacy of arbitray time-dependent prophylaxis against acquiring infection biorxiv.org/cgi/content/shor…
We submitted a few new papers on modelling PrEP efficacy: a) Mechanisms of combinatorial efficacy of Truvada and b) efficient numerical methods to estimate PrEP efficacy. The latter may be used in a health App to help PrEP users to plan and monitor individual protection levels...
Check out our novel method for estimating SARS-CoV-2 incidence only from sequence data; medrxiv viewer disq.us/t/3x1ofwh
The Lab developed novel Tools to fight SARS-CoV2, which will be presented at the COVID Dynamics and Evolution conference: shorturl.at/gBLR3. a) A Software to compute quarantine, isolation and testing strategies and b) an incidence estimator based on SARS-CoV2 genetics.